HOOKIPA Pharma Inc. (HOOK)

$ 1.76
-0.21 (-10.66%)
-
Symbol HOOK
Price $ 1.76
Beta 1.005
Volume Avg. 0.24M
Market Cap 0.053B
Shares () -
52 Week Range 1.75-20.0
1y Target Est -
DCF Unlevered HOOK DCF ->
DCF Levered HOOK LDCF ->
ROE -50.48% Strong Sell
ROA -47.06% Strong Sell
Operating Margin -
Debt / Equity 31.54% Neutral
P/E -
P/B 0.54 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest HOOK news


Mr. Joern Aldag
Healthcare
Biotechnology
Nasdaq Global Select

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.